摘要
Abstract
Objective:To explore the effects of Taxol + Carboplatin(TC)chemotherapy combined with Bevacizumab on immune function and short-term efficacy in patients with locally advanced non-small cell lung cancer(LANSCLC).Method:The medical records of 100 patients with LANSCLC who were treated in Pingxiang People's Hospital from October 2018 to September 2020 were retrospectively analyzed.57 cases who were treated with TC chemotherapy combined with Bevacizumab were included in combined group,and 43 cases who were treated with TC chemotherapy were enrolled as contrast group.Patients in both groups were treated for 4 consecutive cycles(3 weeks for one cycle).The differences in clinical efficacy[disease control rate(DCR),objective response rate(ORR)]after 1 month of treatment,differences in angiogenesis markers[vascular endothelial growth factor(VEGF),hepatoma-derived growth factor(HDGF),basic fibroblast growth factor(BFGF)]and immune function(CD3+,CD4+,CD4+/CD8+)before and after treatment,differences in incidence rates of toxic and side effects during treatment and differences in progression-free survival(PFS)and overall survival(OS)during follow-up were compared between the two groups.Result:After 1 month of treatment,DCR and ORR in combined group were higher than those in contrast group(P<0.05).After treatment,the levels of VEGF,HDGF and BFGF in both groups were decreased compared with those before treatment,and those in combined group were lower than those in contrast group(P<0.05).The levels of CD3+,CD4+ and CD4+/CD8+ in the two groups were reduced after treatment compared with those before treatment,but those in combined group were higher than those in contrast group(P<0.05).There were no significant differences in the incidence of toxic and side effects between the two groups during treatment(P>0.05).During follow-up,the median PFS and median OS in combined group were longer than those in contrast group(P<0.05).Conclusion:TC chemotherapy combined with Bevacizumab can effectively improve the short-term efficacy and immune function and prolong the survival of patients with LANSCLC,and it has certain safety.关键词
TC方案化疗/贝伐珠单抗/非小细胞肺癌/近期疗效/免疫功能Key words
TC chemotherapy/Bevacizumab/Non-small cell lung cancer/Short-term efficacy/Immune function
